Pharmaceuticals, Biotechnology and Life Sciences
Innovent Biologics has dosed the first patient in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.
Array BioPharma’s updated results from the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI (encorafenib), a BRAF inhibitor, MEKTOVI (binimetinib), a MEK inhibitor and ERBITUX (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), was generally well-tolerated with no unexpected toxicities.
Amneal Pharmaceuticals will shortly start selling its prescription medicine used to treat memory problems associated with Alzheimer’s disease.Rivastigmine Transdermal System, generic version of Novartis’ Exelon Patch, after getting the FDA’s approval.
Dechra continues to deliver above market revenue growth in our existing business and in our acquisitions, in line with the Board’s expectations, Ian Page, Chief Executive Officer, said in company’s half year trading period update, which highlights growth in European and North American pharmaceuticals net revenue, as well as the Laboratories Vancofarma do Brasil acquisition.
Verona Pharma’s testing nebulized ensifentrine given twice daily in two doses, on top of inhaled Stiolto, Respimat, to treat COPD patients, misses primary endpoint of peak forced expiratory volume in one second, on day 3 of treatment.
A Seattle-based privately held biopharmaceutical company, Sound Pharmaceuticals (SPI), said Monday it is advancing Phase 2 hearing loss clinical trial in Cystic Fibrosis, to study SPI-1005 in patients who are receiving intravenous (IV) tobramycin to treat acute pulmonary exacerbation.
IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model, in a virtual Chief Commercial Officer partnership, to run for five years, designed to provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA after monetisation.
Ipsen has presented results of Dysport and botulinum toxins pipeline, from basic science to clinical phases, and patients and caregivers surveys, highlighting differentiation of Dysport in the treatment of spasticity and movement disorders.
ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
Blue Water Vaccines, a privately held company, will complete its fund-raising of $15 million to support the flu vaccine program, after agreeing with the University of Oxford, without disclosing terms of the agreement, providing Blue Water Vaccines the option to exclusively license a novel and potentially revolutionary universal influenza vaccine.